You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Finnish Diabetes Risk Score Identifies Benefits of Lifestyle Intervention

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Laurie Barclay, MD
  • CME Released: 6/9/2008
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/9/2009, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, endocrinologists, diabetologists, and other specialists who care for patients at risk for type 2 diabetes.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe the efficacy of the Finnish Diabetes Risk Score in identifying high-risk groups that would benefit from intensive lifestyle intervention to prevent type 2 diabetes.
  2. Describe the efficacy of other risk factors in identifying high-risk groups that would benefit from intensive lifestyle intervention to prevent type 2 diabetes.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay, MD, is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    Brande Nicole Martin is the News CME editor for Medscape Medical News.

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

CME Author(s)

  • Laurie Barclay, MD

    Freelance reviewer and writer for Medscape

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.


    AAFP Accreditation Questions

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Finnish Diabetes Risk Score Identifies Benefits of Lifestyle Intervention

Authors: News Author: Laurie Barclay, MD CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 6/9/2008

Valid for credit through: 6/9/2009, 11:59 PM EST

processing....

June 9, 2008 — The Finnish Diabetes Risk Score (FINDRISC) was effective in identifying high-risk groups that would benefit from intensive lifestyle intervention to prevent type 2 diabetes, according to the results of a randomized controlled trial reported in the May issue of Diabetes Care.

"Intensive lifestyle intervention significantly reduced diabetes incidence among the participants in the Finnish Diabetes Prevention Study (DPS)," write Jaana Lindström, PhD, from the National Public Health Institute in Helsinki, Finland, and colleagues from the Finnish DPS Group. "We investigated whether and to what extent risk factors for type 2 diabetes and other baseline characteristics of the study participants modified the effectiveness of the lifestyle intervention."

In this study, overweight, middle-aged volunteers with impaired glucose tolerance were randomized to an intensive lifestyle intervention (n = 265) or to a control group (n =257) for a median of 4 years, during which annual oral glucose tolerance testing determined diabetes status.

Incidence rates of diabetes and hazard ratios (HRs) for the intervention vs the control group were calculated by sex and baseline tertiles of age, body mass index (BMI), waist circumference, plasma glucose concentration at fasting and 2 hours after a glucose load, fasting serum insulin and insulin resistance index, and categories of composite baseline FINDRISC. The investigators determined interactions between the intervention assignment and baseline risk factors on the risk for diabetes.

Groups in which the intervention was most effective were the oldest individuals (HRs 0.77, 0.49, and 0.36 by increasing age tertiles, respectively; P for interaction = .0130) and those with high baseline FINDRISC (HRs 1.09, 0.84, 0.34, and 0.22 by increasing risk score category, respectively; P for interaction = .0400). Other baseline characteristics or risk factors did not modify the effect of the intervention on the risk for diabetes.

"The FINDRISC may be useful in identifying high-risk groups most likely to benefit from intensive lifestyle intervention to prevent type 2 diabetes," the study authors write.

Limitations of this study include careful selection of DPS participants, limiting generalizability to other populations with differing risk profiles.

"Intensive lifestyle intervention in individuals with IGT [impaired glucose tolerance] was most effective among those with higher baseline age or a high FINDRISC," the study authors write. “To improve cost-effectiveness, the FINDRISC could be used to identify target groups for lifestyle intervention to prevent type 2 diabetes."

The DPS study has been supported by the Academy of Finland, the Juho Vainio Foundation, Ministry of Education, the Novo Nordisk Foundation, the Yrjö Jahnsson Foundation, and the Finnish Diabetes Research Foundation, and by competitive research funding from Tampere, Kuopio, and Oulu University Hospitals. The costs of publication of this article were defrayed in part by the payment of page charges, mandating that it must therefore be hereby marked "advertisement" solely to indicate this fact.

Diabetes Care. 2008;31:857-862.

Clinical Context

Although randomized controlled trials have shown that lifestyle intervention in individuals with impaired glucose tolerance may prevent or postpone progression to overt type 2 diabetes, the effect of lifestyle intervention varies among individuals. Risk reduction in diabetes incidence requires compliance with the lifestyle intervention goals.

It has not previously been determined whether baseline risk factors for type 2 diabetes or other characteristics could modify the effectiveness of lifestyle intervention to reduce diabetes risk. Identifying individuals most likely to benefit from lifestyle intervention could direct intensified actions to these groups, decreasing the number needed to treat while reducing costs.

Study Highlights

  • Participants in DPS had impaired glucose tolerance on the basis of 2 consecutive oral glucose tolerance tests, were middle-aged (40 - 64 years), and were overweight (BMI > 25 kg/m2) at baseline.
  • Of 522 participants, 172 were men and 350 were women.
  • In DPS, intensive lifestyle intervention significantly reduced diabetes incidence.
  • The goal of this analysis was to determine whether, and to what extent, risk factors for type 2 diabetes, the composite FINDRISC, and other baseline characteristics modified the effectiveness of lifestyle intervention in reducing diabetes incidence.
  • FINDRISC is a simple risk assessment tool for population screening that characterizes individuals according to their future diabetes risk. It is a paper-and-pencil screening questionnaire that takes only a few minutes to complete and does not require trained personnel or laboratory equipment.
  • FINDRISC was developed and validated with 2 large, population-based cohorts. It combines the effects of 8 risk characteristics and estimates the 10-year absolute risk for type 2 diabetes.
  • In DPS, participants were randomized to an intensive lifestyle intervention (n = 265) or to a control group (n = 257).
  • Median duration of follow-up was 4 years; oral glucose tolerance testing was performed each year to determine diabetes status.
  • Incidence rates of diabetes and HRs for the intervention vs the control group were calculated by sex and baseline tertiles of age, BMI, waist circumference, plasma glucose concentration at fasting and 2 hours after a glucose load, fasting serum insulin and insulin resistance index, and categories of composite baseline FINDRISC.
  • Groups in which the intervention was most effective were the oldest individuals (HRs 0.77, 0.49, and 0.36 by increasing age tertiles; P for interaction = .0130) and those with high baseline FINDRISC (HRs: 1.09, 0.84, 0.34, and 0.22 by increasing risk score category; P for interaction = .0400).
  • For participants with low baseline FINDRISC scores, the diabetes incidence rates remained virtually the same (3.6 - 4.7 cases/100 person-years) regardless of intervention.
  • Participants with high baseline FINDRISC scores who received intensive lifestyle counseling had a similarly low incidence rate of diabetes (4.0 - 4.2).
  • Participants with a high baseline FINDRISC who received only standard care counseling had a very high incidence rate (11.7 - 18.8), suggesting that the originally increased risk in individuals with a high FINDRISC score was completely abolished with lifestyle intervention.
  • This interaction was not explained by better adherence to the intervention goals.
  • With the FINDRISC as a prescreening method, the cost-efficiency of lifestyle interventions could be drastically increased, with the number needed to treat among the entire study population in the DPS reduced from 7.7 to 3.6.
  • The intervention was most effective among the oldest individuals (age > 61 years), with a relative risk reduction of 64% vs that in the control group.
  • Except for FINDRISC score and age, other baseline characteristics or risk factors did not modify the effect of the intervention on the risk for the development of diabetes.
  • Although the incidence of diabetes increased with increasing BMI and waist circumference in both intervention and control groups, the effect of lifestyle intervention was of the same magnitude in all BMI groups.
  • The investigators concluded that the FINDRISC may identify high-risk groups most likely to benefit from intensive lifestyle intervention to prevent type 2 diabetes and that use of the FINDRISC to identify target groups for lifestyle intervention could improve cost effectiveness.

Pearls for Practice

  • FINDRISC may identify high-risk groups most likely to benefit from intensive lifestyle intervention to prevent type 2 diabetes. By using the FINDRISC as a prescreening method, the cost-efficiency of lifestyle interventions could be drastically increased.
  • Intensive lifestyle intervention was most effective among the oldest individuals (age > 61 years), with a relative risk reduction of 64% vs that in the control group. Except for FINDRISC score and age, other baseline characteristics or risk factors did not modify the effect of the intervention on the risk for the development of diabetes.

CME Test

  • Print